Benign prostatic hyperplasia (BPH) is a prevailing disease that affects the majority of men during the aging process. Men with progressive symptoms should receive either pharmaceutical treatment or surgical intervention. Medical therapy remains the first-line treatment in reducing lower urinary tract symptoms, preventing related complications and achieving improvement in quality of life. Both α1-blockers and 5ARIs are effective and considered the drug-of-choice for BPH treatment. α1-blockers are indicated for rapid symptom treatment and 5ARIs are reserved for men with prostate volume ≥ 30 mL for reducing the risk of complications and surgical intervention. Combinations of α1Jblockers and 5ARIs or α1-blockers plus antimuscarinic agents have also proved to provide benefit for men with moderate to severe symptoms.